3-(2-oxo-1,2-dihydro-4-quinolinyl)-L-alanine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 3-(2-oxo-1,2-dihydro-4-quinolinyl)-L-alanine
• 英文别名: (S)-2-amino-3-[2(1H)-quinolone-4]propionic acid；(2S)-2-azaniumyl-3-(2-oxo-1H-quinolin-4-yl)propanoate
• 化学式: C₁₂H₁₂N₂O₃
• 分子量: 232.239
• InChiKey: NOILRCJONSGSRP-VIFPVBQESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.8
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  96.9
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-(2-oxo-1,2-dihydro-4-quinolinyl)-L-alanine 、 2-[(琥珀酰亚胺氧基)羰基]苯甲酸甲酯 在 sodium carbonate 作用下， 以 水 、 乙腈 为溶剂， 以19%的产率得到(2S)-2-(1,3-dioxo-2,3-dihydro-1H-isoindol-2-yl)-3-(2-oxo-1,2-dihydroquinolin-4-yl)propanoic acid
  参考文献：
  名称：

  Synthesis and Evaluation of Analogues of N-Phthaloyl-l-tryptophan (RG108) as Inhibitors of DNA Methyltransferase 1

  摘要：

  DNA methyltransferases (DNMT) are promising drug targets in cancer provided that new, more specific, and chemically stable inhibitors are discovered. Among the non-nucleoside DNMT inhibitors, N-phthaloyl-L-tryptophan 1 (RG108) was first identified as inhibitor of DNMT1. Here, 1 analogues were synthesized to understand its interaction with DNMT. The indole, carboxylate, and phthalimide moieties were modified. Homologated and conformationally constrained analogues were prepared. The latter were synthesized from prolinohomotryptophan derivatives through a methodology based amino-zinc-ene-enolate cyclization. All compounds were tested for their ability to inhibit DNMT1 in vitro. Among them, constrained compounds 16-18 and NPys derivatives 10-11 were found to be at least 10-fold more potent than the reference compound. The cytotoxicity on the tumor, DU145 cell line of the most potent inhibitors was correlated to their inhibitory potency. Finally, docking studies were conducted in order to understand their binding mode. This study provides insights for the design of the next-generation of DNMT inhibitors.

  DOI：

  10.1021/jm401419p
• 作为产物：
  描述：

  L-天门冬氨酸 、 2-喹啉醇 在 dipotassium peroxodisulfate 、 silver nitrate 作用下， 以 水 、 乙腈 为溶剂， 反应 3.0h， 以39%的产率得到3-(2-oxo-1,2-dihydro-4-quinolinyl)-L-alanine
  参考文献：
  名称：

  一种瑞巴派特中间体的合成方法

  摘要：

  本发明公开了一种合成瑞巴派特关键中间体2‑氨基‑3‑[2(1H)‑喹诺酮‑4]丙酸的新方法。该方法包括将天冬氨酸经与2‑羟基喹啉反应制备瑞巴派特关键中间体2‑氨基‑3‑[2(1H)‑喹诺酮‑4]丙酸，再与对氯苯甲酰氯缩合反应即可制备瑞巴派特。所述中间体合成方法原料价廉易得，反应步骤短、光学纯度好。。

  公开号：

  CN108341775B

文献信息

• 2-Quinoxalinol Salen Compounds and Uses Thereof
  申请人：Gorden Anne E. V.

  公开号：US20090286968A1

  公开（公告）日：2009-11-19

  Disclosed are 2-quinoxalinol salen compounds and in particular 2-quinoxalinol salen Schiff-base ligands. The disclosed 2-quinoxalinol salen compounds may be utilized as ligands for forming complexes with cations, and further, the formed complexes may be utilized as catalysts for oxidation reactions. The disclosed 2-quinoxalinol salen compounds also may be conjugated to solid supports and utilized in methods for selective solid-phase extraction or detection of cations.

  本文披露了2-喹啉醇Salen化合物，特别是2-喹啉醇Salen席夫碱配体。披露的2-喹啉醇Salen化合物可用作与阳离子形成络合物的配体，进而形成的络合物可用作氧化反应的催化剂。披露的2-喹啉醇Salen化合物还可以与固体支撑物结合，并用于选择性固相萃取或阳离子检测方法。
• Stabilized minimal coiled-coil mimetics
  申请人：NEW YORK UNIVERSITY

  公开号：US10851133B2

  公开（公告）日：2020-12-01

  This invention relates to a macrostructure that includes an antiparallel coiled-coil structure shown below or a parallel coiled-coil structure shown below and described in the present application.

  本发明涉及一种宏观结构，它包括下图所示的反平行盘卷结构或下图所示的平行盘卷结构，并在本申请中进行了描述。
• Therapeutic peptides
  申请人：COHBAR, INC.

  公开号：US11111271B2

  公开（公告）日：2021-09-07

  Provided herein are peptides and peptide analogs and methods of treating a metabolic disease, e.g., obesity, diabetes, methods of treating cancer, methods of treating a liver disease, and methods of modulating fatty acid metabolism.

  本文提供了肽和肽类似物以及治疗代谢性疾病的方法，例如肥胖症、糖尿病、治疗癌症的方法、治疗肝病的方法以及调节脂肪酸代谢的方法。
• Peptide inhibitors of transcription factor aggregation
  申请人：ADRX, INC.

  公开号：US11117930B2

  公开（公告）日：2021-09-14

  This invention relates to materials, such as peptides, and methods to inhibit the aggregation transcription factors, for example p53 inhibitors, p63 inhibitors and p73 inhibitors. More specifically, the invention relates to cancer chemotherapeutics. More specifically, the invention provides pharmaceutical compositions and methods of treating cancer with certain peptides.

  本发明涉及抑制转录因子（例如 p53 抑制剂、p63 抑制剂和 p73 抑制剂）聚集的材料（例如肽）和方法。更具体地说，本发明涉及癌症化疗药物。更具体地说，本发明提供了用某些肽治疗癌症的药物组合物和方法。
• STABILIZED MINIMAL COILED-COIL MIMETICS
  申请人：New York University

  公开号：EP3303367A1

  公开（公告）日：2018-04-11